Maryam Shabihkhani
University of California, Los Angeles
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maryam Shabihkhani.
Clinical Biochemistry | 2014
Maryam Shabihkhani; Gregory M. Lucey; Bowen Wei; Sergey Mareninov; Jerry J. Lou; Harry V. Vinters; Elyse J. Singer; Timothy F. Cloughesy; William H. Yong
Well preserved frozen biospecimens are ideal for evaluating the genome, transcriptome, and proteome. While papers reviewing individual aspects of frozen biospecimens are available, we present a current overview of experimental data regarding procurement, storage, and quality assurance that can inform the handling of frozen biospecimens. Frozen biospecimen degradation can be influenced by factors independent of the collection methodology including tissue type, premortem agonal changes, and warm ischemia time during surgery. Rapid stabilization of tissues by snap freezing immediately can mitigate artifactually altered gene expression and, less appreciated, protein phosphorylation profiles. Collection protocols may be adjusted for specific tissue types as cellular ischemia tolerance varies widely. If data is not available for a particular tissue type, a practical goal is snap freezing within 20min. Tolerance for freeze-thaw events is also tissue type dependent. Tissue storage at -80°C can preserve DNA and protein for years but RNA can show degradation at 5years. For -80°C freezers, aliquots frozen in RNAlater or similar RNA stabilizing solutions are a consideration. It remains unresolved as to whether storage at -150°C provides significant advantages relative to that at -80°C. Histologic quality assurance of tissue biospecimens is typically performed at the time of surgery but should also be conducted on the aliquot to be distributed because of tissue heterogeneity. Biobanking protocols for blood and its components are highly dependent on intended use and multiple collection tube types may be needed. Additional quality assurance testing should be dictated by the anticipated downstream applications.
Clinical Biochemistry | 2014
Jerry J. Lou; Leili Mirsadraei; Desiree E. Sanchez; Ryan W. Wilson; Maryam Shabihkhani; Gregory M. Lucey; Bowen Wei; Elyse J. Singer; Sergey Mareninov; William H. Yong
UNLABELLED Frozen biospecimens are crucial for translational research and contain well-preserved nucleic acids and protein. However, the risks of freezer failure as well as space, cost, and environmental concerns of frozen biospecimens are substantial. OBJECTIVE The purpose of the study was to review the current status of room temperature biospecimen storage. METHODS We searched Pubmed and vendor websites to identify relevant information. RESULTS Formalin-fixed paraffin embedded (FFPE) tissues have great value but their use is limited by cross-linking and fragmentation of nucleic acids, as well as loss of enzymatic activity. Stabilization solutions can now robustly preserve fresh tissue for up to 7days at room temperature. For longer term storage, commercial vendors of chemical matrices claim real time stability of nucleic acids of over 2 years and their accelerated aging studies to date suggest stability for 12years for RNA and 60years for DNA. However, anatomic pathology biorepositories store mostly frozen tissue rather than nucleic acids. Small quantities of tissue can be directly placed on some chemical matrices to stabilize DNA, however RNA and proteins are not preserved. Current lyophilization approaches can preserve histomorphology, DNA, RNA, and proteins though RNA shows moderate degradation after 1-2years. Formalin-free fixatives show improved but varying abilities to preserve nucleic acids and face validation as well as cost barriers in replacing FFPE specimens. The paraffin embedding process can degrade RNA. CONCLUSION Development of robust long-term room temperature biospecimen tissue storage technology can potentially reduce costs for the biomedical community in the face of growing targeted therapy needs and decreasing budgets.
Molecular Imaging and Biology | 2015
Elena Karavaeva; Robert J. Harris; Kevin Leu; Maryam Shabihkhani; William H. Yong; Whitney B. Pope; Albert Lai; Phioanh L. Nghiemphu; Linda M. Liau; Wei Chen; Johannes Czernin; Timothy F. Cloughesy; Benjamin M. Ellingson
PurposeDiffusion magnetic resonance imaging (MRI) and 6-[18F]fluoro-l-dopa ([18F]FDOPA) positron emission tomography (PET) are used to interrogate malignant tumor microenvironment. It remains unclear whether there is a relationship between [18F]FDOPA uptake, diffusion MRI estimates of apparent diffusion coefficient (ADC), and mitotic activity in the context of recurrent malignant gliomas, where the tumor may be confounded by the effects of therapy. The purpose of the current study is to determine whether there is a correlation between these imaging techniques and mitotic activity in malignant gliomas.ProceduresWe retrospectively examined 29 patients with recurrent malignant gliomas who underwent structural MRI, diffusion MRI, and [18F]FDOPA PET prior to surgical resection. Qualitative associations were noted, and quantitative voxel-wise and median measurement correlations between [18F]FDOPA PET, ADC, and mitotic index were performed.ResultsAreas of high [18F]FDOPA uptake exhibited low ADC and areas of hyperintensity T2/fluid-attenuated inversion recovery (FLAIR) with low [18F]FDOPA uptake exhibited high ADC. There was a significant inverse voxel-wise correlation between [18F]FDOPA and ADC for all patients. Median [18F]FDOPA uptake and median ADC also showed a significant inverse correlation. Median [18F]FDOPA uptake was positively correlated, and median ADC was inversely correlated with mitotic index from resected tumor tissue.ConclusionsA significant association may exist between [18F]FDOPA uptake, diffusion MRI, and mitotic activity in recurrent malignant gliomas.
PLOS ONE | 2015
William H. Yong; Maryam Shabihkhani; Donatello Telesca; Shuai Yang; Jonathan L. Tso; Jimmy C. Menjivar; Bowen Wei; Gregory M. Lucey; Sergey Mareninov; Zugen Chen; Linda M. Liau; Albert Lai; Stanley F. Nelson; Timothy F. Cloughesy; Cho-Lea Tso
Glioblastoma stem cells (GSC) co-exhibiting a tumor-initiating capacity and a radio-chemoresistant phenotype, are a compelling cell model for explaining tumor recurrence. We have previously characterized patient-derived, treatment-resistant GSC clones (TRGC) that survived radiochemotherapy. Compared to glucose-dependent, treatment-sensitive GSC clones (TSGC), TRGC exhibited reduced glucose dependence that favor the fatty acid oxidation pathway as their energy source. Using comparative genome-wide transcriptome analysis, a series of defense signatures associated with TRGC survival were identified and verified by siRNA-based gene knockdown experiments that led to loss of cell integrity. In this study, we investigate the prognostic value of defense signatures in glioblastoma (GBM) patients using gene expression analysis with Probeset Analyzer (131 GBM) and The Cancer Genome Atlas (TCGA) data, and protein expression with a tissue microarray (50 GBM), yielding the first TRGC-derived prognostic biomarkers for GBM patients. Ribosomal protein S11 (RPS11), RPS20, individually and together, consistently predicted poor survival of newly diagnosed primary GBM tumors when overexpressed at the RNA or protein level [RPS11: Hazard Ratio (HR) = 11.5, p<0.001; RPS20: HR = 4.5, p = 0.03; RPS11+RPS20: HR = 17.99, p = 0.001]. The prognostic significance of RPS11 and RPS20 was further supported by whole tissue section RPS11 immunostaining (27 GBM; HR = 4.05, p = 0.01) and TCGA gene expression data (578 primary GBM; RPS11: HR = 1.19, p = 0.06; RPS20: HR = 1.25, p = 0.02; RPS11+RPS20: HR = 1.43, p = 0.01). Moreover, tumors that exhibited unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) or wild-type isocitrate dehydrogenase 1 (IDH1) were associated with higher RPS11 expression levels [corr (IDH1, RPS11) = 0.64, p = 0.03); [corr (MGMT, RPS11) = 0.52, p = 0.04]. These data indicate that increased expression of RPS11 and RPS20 predicts shorter patient survival. The study also suggests that TRGC are clinically relevant cells that represent resistant tumorigenic clones from patient tumors and that their properties, at least in part, are reflected in poor-prognosis GBM. The screening of TRGC signatures may represent a novel alternative strategy for identifying new prognostic biomarkers.
Methods of Molecular Biology | 2014
William H. Yong; Sarah M. Dry; Maryam Shabihkhani
Powerful technologies critical to personalized medicine and targeted therapeutics require the analysis of carefully validated, procured, stored, and managed biospecimens. Reflecting advancements in biospecimen science, the National Cancer Institute and the International Society for Biological and Environmental Repositories are periodically publishing best practices that can guide the biobanker. The modern biobank will operate more like a clinical laboratory with formal accreditation, standard operating procedures, and quality assurance protocols. This chapter highlights practical issues of consent, procurement, storage, quality assurance, disbursement, funding, and space. Common topics of concern are discussed including the differences between clinical and research biospecimens, stabilization of biospecimens during procurement, optimal storage temperatures, and technical validation of biospecimen content and quality. With quickly expanding biospecimen needs and limited healthcare budgets, biobanks may need to be selective as to what is stored. Furthermore, a shift to room-temperature storage modalities where possible can reduce long-term space and fiscal requirements.
Advances in Experimental Medicine and Biology | 2014
Ladan Vakili; Kaveh Navab; Maryam Shabihkhani; Nasim Pourtabatabaei; Samra Vazirian; Zarina Barseghian; Seyedehsara Seyedali; Greg Hough
Serum paraoxonase 1 (PON1) has been shown to act as an important guardian against cellular damage from oxidized lipids in low-density lipoprotein (LDL), plasma membrane, against toxic agents such as pesticide residues including organophosphates and against bacterial endotoxin. PON1 associated with circulating high-density lipoprotein (HDL) has the ability to prevent the generation of pro inflammatory oxidized phospholipids by reactive oxygen species. The activities of the HDL-associated PON1 and several other anti-inflammatory factors in HDL are in turn negatively regulated by these oxidized lipids. In rabbits, mice, and humans there appears to be an increase in the formation of these oxidized lipids during the acute phase response. This results in the association of acute phase proteins with HDL and inhibition of the HDL-associated PON1 that renders HDL pro inflammatory.In populations, low serum HDL-cholesterol is a risk factor for atherosclerosis and efforts are directed toward therapies to improve the quality and the relative concentrations of LDL and HDL. Apolipoprotein A-I (apoA-I) has been shown to reduce atherosclerotic lesions in laboratory animals. ApoA-I, however, is a large protein that is costly and needs to be administered parenterally. Our group has developed apoA-I mimetic peptides that are much smaller than apoA-I (18 amino acids long vs 243 in ApoA-I itself). These HDL mimetic peptides are much more effective in removing the oxidized phospholipids and other oxidized lipids. They improve LDL and HDL composition and function and reduce lesion formation in animal models of atherogenesis. Following is a brief description of some of the HDL mimetic peptides that can improve HDL and the effect of the peptide on PON1 activity.
Experimental and Molecular Pathology | 2017
Masoud Movassaghi; Maryam Shabihkhani; Seyed Hojat; Ryan R. Williams; Lawrance K. Chung; Kyuseok Im; Gregory M. Lucey; Bowen Wei; Sergey Mareninov; Michael W. Wang; Denise W. Ng; Randy Tashjian; Shino Magaki; Mari Perez-Rosendahl; Isaac Yang; Negar Khanlou; Harry V. Vinters; Linda M. Liau; Phioanh L. Nghiemphu; Albert Lai; Timothy F. Cloughesy; William H. Yong
BACKGROUND Commercial targeted genomic profiling with next generation sequencing using formalin-fixed paraffin embedded (FFPE) tissue has recently entered into clinical use for diagnosis and for the guiding of therapy. However, there is limited independent data regarding the accuracy or robustness of commercial genomic profiling in gliomas. METHODS As part of patient care, FFPE samples of gliomas from 71 patients were submitted for targeted genomic profiling to one commonly used commercial vendor, Foundation Medicine. Genomic alterations were determined for the following grades or groups of gliomas; Grade I/II, Grade III, primary glioblastomas (GBMs), recurrent primary GBMs, and secondary GBMs. In addition, FFPE samples from the same patients were independently assessed with conventional methods such as immunohistochemistry (IHC), Quantitative real-time PCR (qRT-PCR), or Fluorescence in situ hybridization (FISH) for three genetic alterations: IDH1 mutations, EGFR amplification, and EGFRvIII expression. RESULTS A total of 100 altered genes were detected by the aforementioned targeted genomic profiling assay. The number of different genomic alterations was significantly different between the five groups of gliomas and consistent with the literature. CDKN2A/B, TP53, and TERT were the most common genomic alterations seen in primary GBMs, whereas IDH1, TP53, and PIK3CA were the most common in secondary GBMs. Targeted genomic profiling demonstrated 92.3%-100% concordance with conventional methods. The targeted genomic profiling report provided an average of 5.5 drugs, and listed an average of 8.4 clinical trials for the 71 glioma patients studied but only a third of the trials were appropriate for glioma patients. CONCLUSIONS In this limited comparison study, this commercial next generation sequencing based-targeted genomic profiling showed a high concordance rate with conventional methods for the 3 genetic alterations and identified mutations expected for the type of glioma. While it may not be feasible to exhaustively independently validate a commercial genomic profiling assay, examination of a few markers provides some reassurance of its robustness. While potential targeted drugs are recommended based on genetic alterations, to date most targeted therapies have failed in glioblasomas so the usefulness of such recommendations will increase with development of novel and efficacious drugs.
Pathology Case Reviews | 2013
William H. Yong; Maryam Shabihkhani; Keng C. Su; Bowen Wei; Gregory M. Lucey; Sergey Mareninov; Lydia E. Kuo-Bonde; Whitney B. Pope; Timothy F. Cloughesy
Abstract As brainstem tumor biopsies are increasingly prevalent, we review the 3 major presentations of brainstem tumors. Diffuse brainstem gliomas are the most common pattern and are usually centered in the pons, particularly in children. We describe the case of an IDH1 R132H mutant adult diffuse medullary glioma that shows loss of phosphatase and tensin homolog (PTEN) at autopsy. Nonenhancing diffuse brainstem gliomas in adults usually reflect a low-grade glioma with a median survival of 5 to 7 years. However, a nonenhancing diffuse brainstem tumor in children is often a glioblastoma with survival of less than a year. An enhancing diffuse brainstem tumor in an adult reflects a high-grade glioma. Midbrain tectal gliomas and exophytic medullary gliomas have indolent courses, and survivals often exceed the available follow-up. The pathology in tectal and exophytic medullary tumors is typically a low-grade diffuse glioma or pilocytic astrocytoma. The genetics of pediatric diffuse pontine gliomas are the best studied and show differences from adult gliomas as well as pediatric nonbrainstem gliomas. Radiation is of value in the malignant brainstem gliomas. However, many trials that add chemotherapy have had disappointing results. While recognition of the 3 patterns informs differential considerations, histopathology remains crucial in rendering an accurate diagnosis. We discuss the histologic and immunohistochemical considerations for excluding other types of tumors and nonneoplastic disorders that can occur in the region. The utility of current molecular markers such as p53, IDH1, 1p/19q codeletion, and BRAF duplications is discussed. Our case suggests that IDH1 status may be diagnostically useful.
Atherosclerosis | 2013
Mohamad Navab; Maryam Shabihkhani; Kaveh Navab; Samra Vazirian; Maryam Haghnegahdar; Srinivasa T. Reddy
Despite the cholesterol lowering beneficial effects of statins, nearly 70% of cardiovascular disease remains unresolved. High density lipoproteins (HDL), apolipoprotein A-I (the major protein component of HDL), and apoA-I mimetic peptides exert antiinflammatory effects but have not been shown to reduce plasma cholesterol levels. Apolipoprotein E (apoE) is a protein component of chylomicron remnants, very low density lipoprotein (VLDL), and HDL. ApoE is ubiquitously expressed and secreted by many tissues in the body including liver, brain, skin, and tissue macrophages [1]. A common well-characterized polymorphism in human apoE gene accounts for the three alleles, e2, e 3a nde4 that are known to confer resistance or susceptibilitytomany diseasesincludingAlzheimer’sdisease[2]and atherosclerosis [3]. ApoE gene encodes for a 299 amino acid protein containing two domains: a receptor-binding domain at the N-ter
Journal of Neuro-oncology | 2017
Maryam Shabihkhani; Donatello Telesca; Masoud Movassaghi; Yalda B. Naeini; Kourosh M. Naeini; Seyed Hojat; Diviya Gupta; Gregory M. Lucey; Michael Ontiveros; Michael W. Wang; Lauren S. Hanna; Desiree E. Sanchez; Sergey Mareninov; Negar Khanlou; Harry V. Vinters; Marvin Bergsneider; Phioanh L. Nghiemphu; Albert Lai; Linda M. Liau; Timothy F. Cloughesy; William H. Yong